S
Scott T. Miller
Researcher at SUNY Downstate Medical Center
Publications - 120
Citations - 7252
Scott T. Miller is an academic researcher from SUNY Downstate Medical Center. The author has contributed to research in topics: Sickle cell anemia & Anemia. The author has an hindex of 35, co-authored 118 publications receiving 6529 citations. Previous affiliations of Scott T. Miller include State University of New York System.
Papers
More filters
Journal ArticleDOI
Cerebrovascular Accidents in Sickle Cell Disease: Rates and Risk Factors
Kwaku Ohene-Frempong,Steven J. Weiner,Lynn A. Sleeper,Scott T. Miller,Stephen H. Embury,John W. Moohr,Doris L. Wethers,Charles H. Pegelow,Frances M. Gill +8 more
TL;DR: The highest rates of prevalence of CVA and incidence were in sickle cell anemia (SS) patients, but CVA occurred in all common genotypes, and the incidence of infarctive CVA was lowest in SS patients 20 to 29 years of age and higher in children and older patients.
Journal ArticleDOI
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Scott T. Miller,Lynn A. Sleeper,Charles H. Pegelow,Laura E. Enos,Winfred C. Wang,Steven J. Weiner,Doris L. Wethers,Jeanne Smith,Thomas R. Kinney +8 more
TL;DR: Three easily identifiable manifestations of sicklecell disease that may appear in the first two years of life (dactylitis, severe anemia, and leukocytosis) can help to predict the possibility of severe sickle cell disease later in life.
Journal Article
Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease.
Armstrong Fd,Robert J. Thompson,Winfred C. Wang,Robert A. Zimmerman,Charles H. Pegelow,Scott T. Miller,Franklin G. Moser,Jacqueline A. Bello,Hurtig A,Vass K +9 more
TL;DR: The results substantiate the importance of careful evaluation, educational planning, and medical intervention for CNS-related complications in children with sickle cell disease.
Journal ArticleDOI
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TL;DR: High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.
Journal ArticleDOI
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.
Charles H. Pegelow,Robert J. Adams,Virgil McKie,Miguel R. Abboud,Brian Berman,Scott T. Miller,Nancy F. Olivieri,Elliott Vichinsky,Winfred C. Wang,Donald Brambilla +9 more
TL;DR: It is concluded that maintenance of hemoglobin S at a level less than 30% appears to be effective in reducing the rate of recurrent infarction but does not prevent transient neurologic events.